Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of recombinant human alkaline phosphatase in sepsis-associated acute kidney injury
NL-OMON55312Phase 3Active, not recruiting
- Sponsor
- AM-Pharma
- Start
- Nov 2020
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute kidney failure (AKF) and sepsis (2 arms), sponsored by AM-Pharma. Primary endpoint: 28-day all-cause mortality. Started Nov 2020; status: active, not recruiting.
02
Conditions
acute kidney failure (AKF)sepsis
Beyond the preview
Go deeper on NL-OMON55312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55312.